Navigation Links
Head to the Hill Advocacy Day Draws Hundreds to Capitol Hill to Speak-up for the Vital Needs of the Brain Tumor Community
Date:5/7/2013

ain tumor community, which has only seen four (4) FDA-approved treatments in the past three decades.

Recent government-funded projects like The Cancer Genome Atlas (TCGA) have produced significant scientific discoveries in brain tumor research. However, additional investment - on the scale that only the government can provide - in basic science is still needed to develop potential new therapeutics for the patient community.

However, the deep cuts to NIH triggered through sequestration, are expected to result in funding reductions for critical brain tumor research. National Brain Tumor Society and its advocates told their representatives today that it is critical for the federal government to increase NIH funding, so that it may keep pace with the needs of biomedical research.

Temodar (temozolomide) is the standard of care for all brain tumor patients whose treatment includes chemotherapy. Temodar is almost exclusively administered orally, and for this reason health insurance companies often treat it differently. Oral chemotherapy agents are often covered as prescription drugs, rather than a medical benefit, such as traditional intravenous chemotherapy. The result is that patients are often subjected to onerous monthly co-pays in order to access the only chemotherapy available to treat their brain tumor.

Thus, the National Brain Tumor Society supported the reintroduction of [HR 1801] the Cancer Drug Coverage Parity Act. The bill will prohibit health insurance plans from charging patients more to access oral chemotherapy drugs, including Temodar, than they would for traditional IV chemotherapy. National Brain Tumor Society played a crucial role in crafting the newest version of the bill, and is now mobilizing brain tumor patients and families across the country to urge Congress to support the legislation.

More than 688,000 Americans are currently living with a primary brain tumor, and an estimated 14,000 people with die becaus
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Save The Cord Foundation, a Global Leader in Cord Blood Advocacy, Announces its Expansion of Educational Information Surrounding Other Non-Controversial Stem Cell Sources
2. UCSB summit draws key leaders to discuss innovations in energy efficiency science and technology
3. 3M Withdraws Blackmail Claims Against Harvey Boulter From New York Court
4. Assemblyman Levine Presents Resolution Recognizing Rare Disease Day at Capitol
5. NDIA, NTSA Will Be On Hand At Seventh Annual Capitol Hill Modeling and Simulation Expo, Set To Focus On Homeland Security, First Response
6. SPIE Defense, Security, and Sensing 2013 Highlights Vital Role of Photonics for Defense and Commercial Applications
7. New NIST microscope measures nanomagnet property vital to spintronics
8. Palomar Medical Center in San Diego County Introduces New Wrist-Worn Wireless Patient Vital Signs Device
9. Can You Be Too Old for Acne? Probiotic Action comments on news from The Vitals Blog
10. Eckert & Ziegler Vitalea Science and Korea-based BioCore Bring Human Microdosing to Korea to Address the Needs of the Emergent Pharmaceutical Industry
11. Medical vital-sign monitoring reduced to the size of a postage stamp
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), a ... of autologous cell therapies, announced today the publication of ... conjunction with co-authors from Kyoto University and the University ... clinical research using dermal sheath cup (DSC) cells to ... paper entitled " Hair Follicle Dermal Stem Cells Regenerate ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 ... peer-reviewed publication of original research, reviews and editorials ... and clinical practice, today published a provocative article ... the development, progression and potential treatment of prostate ... endocrinology research and proposes the possibility that there ...
(Date:12/19/2014)... December 19, 2014 Charm Sciences is ... for the Detection of Aflatoxin M1 in raw commingled ... independent third party validation. The peer reviewed report of ... the Institute for Agricultural and Fisheries Research (ILVO-T&V) has ... , Aflatoxin B1, the most toxic aflatoxin and a ...
(Date:12/19/2014)... 19, 2014 Bina Technologies, Inc. (Bina, ... they have been acquired by Roche (SIX: RO, ROG; ... held company that provides a big data platform for ... data for the academic and translational research markets.  Bina ... will continue to focus on development of their innovative ...
Breaking Biology Technology:Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... Inc. announced today the dosing of the first ... AEG35156, their targeted antisense therapeutic in mid-stage development ... "A Phase 2, Multicenter, Open-Label, Randomized Study of ... Given In Combination With Carboplatin/Paclitaxel or the Combination ...
... DNDN ) today announced that management will present at the ... Thursday, January 15, 2009 at 11:00 a.m. PT. , ... through the Investor Relations section of the Dendreon website, ... live webcast, it will be archived on the site following ...
... Jan. 8 Amicus Therapeutics (Nasdaq: FOLD ... Ph.D., to its Board of Directors. Dr. Barer ... Celgene Corporation. As an industry veteran, Dr. Barer ... reputation as a trusted and respected leader who has ...
Cached Biology Technology:Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer 2Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors 2
(Date:12/19/2014)... Dec. 18, 2014  23andMe, Inc., the leading personal ... that pinpoints fine-scale differences in genetic ancestry of individuals ... Since immigrants first arrived more than four ... has served as a meeting place for peoples ... and the ongoing mixing of peoples with African, European, ...
(Date:12/17/2014)... Dec. 15, 2014 The Defense Logistics ... easier to detect and prevent counterfeit microcircuits from ... the agency started performing an in-house microcircuit anti-counterfeit ... the authenticity of purchased microcircuits while increasing their ... control measures will be conducted at DLA,s Electronics ...
(Date:12/17/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) ... Chemical Sensor Market 2015-2019" report to their ... One major trend upcoming in this ... in biomedical applications. Chemical sensors help in recording ... during surgical procedures. The Global Chemical Sensor market ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... treatment for stroke has taken a major step forward following ... The University of Manchester have shown in laboratory studies that ... injury and death. , The team, led by Professor Nancy ... of the first small trial of IL-1ra in patients, which ...
... of diseases , A team of international researchers ... 15 regulates inflammation, a finding with implications for ... disease, diabetes, obesity, Alzheimer's, and infections. The ... issue of Nature Genetics. , Investigators believe this ...
... Hopkins researcher, with colleagues in Sweden and at the ... view of cancer as a group of diseases with ... alterations within a cell's nuclear DNA may have to ... January issue of Nature Reviews Genetics, available online Dec. ...
Cached Biology News:Stroke treatment a step closer after trial 2Scientists pinpoint inflammation gene 2Scientists pinpoint inflammation gene 3Scientists pinpoint inflammation gene 4New view of cancer: 'Epigenetic' changes come before mutations 2
... Partek Genomics Solution is a comprehensive ... data visualization specifically designed to reliably ... for high-dimensional genomic studies containing thousands ... fast, memory efficient and will analyze ...
Kit contains: Bio-Rad Amplification Reagent, 2x Amplification Diluent, Streptavidin-HRP, Blocking Reagent, and Phosphate Buffered Saline....
These macrocarriers are for the biolistic PDS-1000 He and Hepta systems. Supplied as 500 macrocarriers....
Intestinal Epithelium Differentiation Environment...
Biology Products: